Anshan Hifichem Past Earnings Performance
Past criteria checks 2/6
Anshan Hifichem's earnings have been declining at an average annual rate of -26.7%, while the Chemicals industry saw earnings growing at 4.9% annually. Revenues have been growing at an average rate of 11.3% per year. Anshan Hifichem's return on equity is 7.5%, and it has net margins of 9.1%.
Key information
-26.7%
Earnings growth rate
-31.4%
EPS growth rate
Chemicals Industry Growth | 12.1% |
Revenue growth rate | 11.3% |
Return on equity | 7.5% |
Net Margin | 9.1% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Anshan Hifichem (SZSE:300758) Might Be Having Difficulty Using Its Capital Effectively
Oct 20Why Investors Shouldn't Be Surprised By Anshan Hifichem Co., Ltd.'s (SZSE:300758) 27% Share Price Surge
Oct 01Anshan Hifichem (SZSE:300758) Has A Somewhat Strained Balance Sheet
Jul 26There's Reason For Concern Over Anshan Hifichem Co., Ltd.'s (SZSE:300758) Massive 30% Price Jump
May 27Anshan Hifichem (SZSE:300758) Could Be Struggling To Allocate Capital
May 06With Anshan Hifichem Co., Ltd. (SZSE:300758) It Looks Like You'll Get What You Pay For
Feb 28Revenue & Expenses Breakdown
How Anshan Hifichem makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 1,483 | 135 | 169 | 89 |
30 Jun 24 | 1,385 | 90 | 178 | 85 |
31 Mar 24 | 1,277 | 47 | 175 | 77 |
31 Dec 23 | 1,218 | 11 | 181 | 81 |
30 Sep 23 | 1,168 | -30 | 190 | 79 |
30 Jun 23 | 1,147 | -40 | 194 | 86 |
31 Mar 23 | 1,149 | -42 | 198 | 91 |
01 Jan 23 | 1,209 | -3 | 192 | 91 |
30 Sep 22 | 1,343 | 53 | 181 | 98 |
30 Jun 22 | 1,370 | 93 | 169 | 92 |
31 Mar 22 | 1,361 | 157 | 150 | 88 |
01 Jan 22 | 1,347 | 180 | 137 | 82 |
30 Sep 21 | 1,248 | 192 | 108 | 73 |
30 Jun 21 | 1,193 | 197 | 104 | 66 |
31 Mar 21 | 1,142 | 187 | 97 | 58 |
31 Dec 20 | 1,008 | 175 | 87 | 51 |
30 Sep 20 | 877 | 141 | 88 | 45 |
30 Jun 20 | 774 | 142 | 72 | 38 |
31 Mar 20 | 724 | 130 | 79 | 32 |
31 Dec 19 | 695 | 108 | 75 | 31 |
30 Sep 19 | 661 | 120 | 69 | 27 |
30 Jun 19 | 664 | 111 | 67 | 27 |
31 Mar 19 | 628 | 100 | 58 | 26 |
31 Dec 18 | 611 | 105 | 58 | 25 |
30 Sep 18 | 606 | 115 | 53 | 22 |
30 Jun 18 | 583 | 110 | 49 | 23 |
31 Mar 18 | 550 | 101 | 46 | 22 |
31 Dec 17 | 553 | 103 | 45 | 21 |
30 Sep 17 | 525 | 100 | 44 | 16 |
30 Jun 17 | 498 | 96 | 233 | 10 |
31 Mar 17 | 470 | 86 | 145 | 5 |
31 Dec 16 | 442 | 76 | 57 | 0 |
30 Sep 16 | 419 | 60 | -32 | 0 |
30 Jun 16 | 396 | 44 | -122 | 0 |
31 Mar 16 | 383 | 41 | -33 | 0 |
31 Dec 15 | 370 | 39 | 55 | 0 |
31 Dec 14 | 323 | 18 | 47 | 0 |
Quality Earnings: 300758 has high quality earnings.
Growing Profit Margin: 300758 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300758's earnings have declined by 26.7% per year over the past 5 years.
Accelerating Growth: 300758 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 300758 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Chemicals industry (-3.6%).
Return on Equity
High ROE: 300758's Return on Equity (7.5%) is considered low.